New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 20, 2014
17:04 EDTSUPN, UTHRSupernus receives $2M milestone payment for launch of Orenitram
Supernus Pharmaceuticals (SUPN) announced that United Therapeutics Corporation (UTHR) has paid Supernus a $2M milestone payment under United Therapeutics' license agreement with Supernus. This payment was due upon the launch of Orenitram Extended-Release Tablets for the treatment of pulmonary arterial hypertension, in the United States. Orenitram utilizes a Supernus patented technology platform. In addition to the launch milestone, Supernus will receive royalties on net sales of Orenitram, and may become entitled to additional milestone payments.
News For SUPN;UTHR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 15, 2014
13:16 EDTUTHRUnited Therapeutics upgraded to Buy from Hold at Standpoint Research
October 14, 2014
09:08 EDTSUPNSupernus announces Paragraph IV ANDA filing for Trokendi XR
Supernus Pharmaceuticals announced that on October 13, the company received a Paragraph IV Notice Letter from Zydus Pharmaceuticals advising Supernus of the filing by Zydus of an Abbreviated New Drug Application seeking approval for topiramate extended-release capsules. Supernus is currently reviewing the details of this Notice Letter and intends to vigorously enforce its intellectual property rights relating to Trokendi XR. The product is currently protected by three issued patents that are listed in the FDA's Orange Book and expire no earlier than 2027.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use